Metabolic syndrome and abnormal glucose metabolism
Conditions
Interventions
Study group:General lifestyle intervention + Jinlida granules, 9g / bag, 1 bag / time, 3 times / day,take it with boiling water
Control group:General lifestyle intervention + placebo, 9g / bag, 1 bag / time, 3 times / day,take it with boiling water
Sponsors
Hebei Yiling Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Subjects aged 18 to 70 years; 2. After the run-in period, subjects should meet the diagnostic criteria for metabolic syndrome; 3. After the run-in period, subjects should meet the diagnostic criteria for impaired glucose tolerance; 4. Subjects who have signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Subjects who have used hypoglycemic drugs in the past 3 months; 2. Subjects with type 1 or type 2 diabetes (T2D), gestational diabetes, secondary diabetes and other special types of diabetes; 3. Hyperthyroidism or hypothyroidism caused by endocrine disorders; 4. Uncontrollable hypertension/hypotension: systolic blood pressure =200mmHg or diastolic blood pressure =110mmHg; or systolic blood pressure =90mmHg or diastolic blood pressure =60mmHg; 5. Comorbidities such as various acute infections, or severe infections, severe anemia and neutropenia; 6. Major disease comorbiditiess, such as active or untreated malignant tumors, or clinical remission of malignant tumors less than 5 years ago; 7. Natural heart disease, such as congenital heart disease, rheumatic heart disease, hypertrophic or dilated cardiomyopathy, NYHA cardiac function classification > III level; 8. Subjects who had any of the following conditions within the past 6 months: coronary intervention (eg: CABG or PTCA), stroke (including ischemic and hemorrhagic stroke); 9. Severe liver and kidney dysfunction (ALT three times greater than the upper limit of the normal and creatinine greater than 132 µmol / l); 10. After the run-in period, fasting TG is less than 5.6mmol/L; 11. Pregnant or, lactating women, and women of childbearing age who have not taken effective contraceptive measures; 12. Participation in any other clinical trials; 13. For any reason, the investigator may consider a subjects inappropriate for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of type 2 diabetes; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in the number of components of the metabolic syndrome;Changes in single indicators (waist circumference, blood pressure, TG, HDL-C) in metabolic syndrome;Carotid intima-media thickness (IMT);Fasting insulin;Ankle brachial index;Glycated hemoglobin (HbA1c);Endothelial function test: Serum NO, ET-1;C-reactive protein;Urinary microalbumin to creatinine ratio (ACR);Incidence of microvascular and macrovascular lesions; | — |
Countries
China
Contacts
Public ContactJia Zhenhua
Hebei Yiling Hospital
Outcome results
None listed